Poor returns led drug developers to exit the antibiotics sector years ago, only for hospital-acquired infections to become a big, deadly and potentially lucrative problem. Big Pharma is returning to the sector, but two academics have a different idea: crowdsource discovery.
Who would argue that Big Pharma marketing isn't changing? Anyone? Well, get ready for even more, Adweek says. Combine Obamacare with technology, social media, Big Data and payer demands, and you have a prescription for pharma sales that's as different from the old days of DTC advertising on network TV as "Father Knows Best" is from "Breaking Bad."
Anyone who has any doubts about how an influx of cash drives a higher volume of R&D work in biotech should check out BDO's new annual report slicing and dicing the numbers at public biotechs in the U.S.
Big Pharma has fought bruising battles in India over intellectual property. China has added compulsory licensing to its bag of tricks for dealing with costly drugs. Now drugmakers can add South Africa to the list of countries that are looking askance at unimpeded patents.
An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure for amyotrophic lateral sclerosis.
Founded and led by hedge fund vet Martin Shkreli, Retrophin has nailed down an agreement to raise $25 million to finance development of a preclinical rare-disease drug and a deal to license a potential autism and schizophrenia compound from an unnamed "major pharmaceutical company." The PIPE financing is expected to close next week.
TransCelerate BioPharma has notched another pre-competitive victory for its Big Pharma and biotech members. The Philadelphia nonprofit has set up a network for companies to score comparator drugs for clinical trials.
A new study shows that Big Pharma has been a "prime target" for cost-cutting as governments sought to lower their healthcare costs. And which governments have hit pharma hardest? Those in Europe's most cash-strapped countries.
Bernard Munos, one of the sharpest critics of the drug development industry, takes Big Pharma to task once again on the innovation front after reviewing just what's been approved over the past 12 years.
New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.